BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D, Černý V, Comin-Colet J, Crespo-Leiro MG, Delgado JF, Édes I, Eremenko AA, Farmakis D, Fedele F, Fonseca C, Fruhwald S, Girardis M, Guarracino F, Harjola VP, Heringlake M, Herpain A, Heunks LM, Husebye T, Ivancan V, Karason K, Kaul S, Kivikko M, Kubica J, Masip J, Matskeplishvili S, Mebazaa A, Nieminen MS, Oliva F, Papp JG, Parissis J, Parkhomenko A, Põder P, Pölzl G, Reinecke A, Ricksten SE, Riha H, Rudiger A, Sarapohja T, Schwinger RH, Toller W, Tritapepe L, Tschöpe C, Wikström G, von Lewinski D, Vrtovec B, Pollesello P. Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. Card Fail Rev 2020;6:e19. [PMID: 32714567 DOI: 10.15420/cfr.2020.03] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Jung P, Seibertz F, Fakuade FE, Ignatyeva N, Sampathkumar S, Ritter M, Li H, Mason FE, Ebert A, Voigt N. Increased cytosolic calcium buffering contributes to a cellular arrhythmogenic substrate in iPSC-cardiomyocytes from patients with dilated cardiomyopathy. Basic Res Cardiol 2022;117:5. [PMID: 35499658 DOI: 10.1007/s00395-022-00912-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Hu Y, Wei Z, Zhang C, Lu C, Zeng Z. The effect of levosimendan on right ventricular function in patients with heart dysfunction: a systematic review and meta-analysis. Sci Rep 2021;11:24097. [PMID: 34916560 DOI: 10.1038/s41598-021-03317-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Kong X, Hu X, Hua B, Fedele F, Farmakis D, Pollesello P. Levosimendan in Europe and China: An Appraisal of Evidence and Context. Eur Cardiol 2021;16:e42. [PMID: 34815750 DOI: 10.15420/ecr.2021.41] [Reference Citation Analysis]
4 Xu J, Song Z, Li L, Liu W, Zhang M, Li J. Effects of different doses of levosimendan combined with Shenmai injection on immune function and galectin-3 and HSP70 levels in rats with acute heart failure. All Life 2021;14:1073-80. [DOI: 10.1080/26895293.2021.2003874] [Reference Citation Analysis]
5 Apostolo A, Vignati C, Della Rocca M, De Martino F, Berna G, Campodonico J, Contini M, Muratori M, Palermo P, Mapelli M, Alimento M, Pezzuto B, Agostoni P. Why Levosimendan Improves the Clinical Condition of Patients With Advanced Heart Failure: A Holistic Approach. J Card Fail 2021:S1071-9164(21)00435-8. [PMID: 34763079 DOI: 10.1016/j.cardfail.2021.10.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang YH, Chen JL, Tsai CS, Tsai YT, Lin CY, Ke HY, Hsu PS. Effects of Levosimendan on Systemic Perfusion in Patients with Low Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Score: Experience from a Single Center in Taiwan. Acta Cardiol Sin 2021;37:512-21. [PMID: 34584384 DOI: 10.6515/ACS.202109_37(5).20210310B] [Reference Citation Analysis]
7 Conti N, Gatti M, Raschi E, Diemberger I, Potena L. Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap. Drug Des Devel Ther 2021;15:3391-409. [PMID: 34376973 DOI: 10.2147/DDDT.S295214] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Petraina A, Nogales C, Krahn T, Mucke H, Lüscher TF, Fischmeister R, Kass DA, Burnett JC, Hobbs AJ, Schmidt HHHW. Cyclic GMP modulating drugs in cardiovascular diseases: Mechanism-based network pharmacology. Cardiovasc Res 2021:cvab240. [PMID: 34270705 DOI: 10.1093/cvr/cvab240] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Haaksma ME, Tuinman PR, Heunks L. Weaning the patient: between protocols and physiology. Curr Opin Crit Care 2021;27:29-36. [PMID: 33337620 DOI: 10.1097/MCC.0000000000000790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Patel SJ, Augoustides JG. Levosimendan and Venoarterial ECMO-A Promising Application. J Cardiothorac Vasc Anesth 2021;35:2496-8. [PMID: 34006467 DOI: 10.1053/j.jvca.2021.03.052] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Heringlake M, Alvarez J, Bettex D, Bouchez S, Fruhwald S, Girardis M, Grossini E, Guarracino F, Herpain A, Toller W, Tritapepe L, Pollesello P. An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety. Expert Rev Cardiovasc Ther 2021;19:325-35. [PMID: 33739204 DOI: 10.1080/14779072.2021.1905520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Nadur NF, de Azevedo LL, Caruso L, Graebin CS, Lacerda RB, Kümmerle AE. The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure. Eur J Med Chem 2021;212:113123. [PMID: 33412421 DOI: 10.1016/j.ejmech.2020.113123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
13 Ibrahim M, Spelde AE, Gutsche JT, Cevasco M, Bermudez CA, Desai ND, Szeto WY, Atluri P, Acker MA, Williams ML. Coronary Artery Bypass Grafting in Cardiogenic Shock: Decision-Making, Management Options, and Outcomes. J Cardiothorac Vasc Anesth 2021;35:2144-54. [PMID: 33268279 DOI: 10.1053/j.jvca.2020.09.108] [Cited by in F6Publishing: 1] [Reference Citation Analysis]